Skip to main content
. 2017 Jun 15;8:15337. doi: 10.1038/ncomms15337

Figure 5. ALDH2 mediates the enhanced cytotoxicity of anthracyclines in VHL-deficient ccRCC cells.

Figure 5

(a–c) The cell growth inhibition rates of the indicated cells (top) and the indicated proteins were detected by western blot (bottom). (a) The primary embryo fibroblast (MEF) cells from ALDH2 knockout mice. ALDH2+/+ and ALDH2−/− represent MEF cells from ALDH2 wild type and knockout mice, then treated by 1 μM doxorubicin for 24 h. (b) RCC4/VHL cells were stably transfected with shRNAs against ALDH2 (#4 and #5), then treated with 1 μM doxorubicin for 48 h. (c) RCC4 cells were stably transfected with ALDH2 expression vector and treated by 1 μM doxorubicin or daunomycin for 24 h. (d,e) The growth inhibition rates of RCC4/VHL cells treated by indicated drugs. (d) RCC4/VHL cells were pretreated with 50 μM ALDH2 activator alda-1 for 1 h, then treated in combination with 1 μM DOX for 48 h. (e) Pretreatment with 60 μM ALDH2 inhibitor daidzin for 24 h, then treated RCC4/VHL cells in combination with 1 μM DOX for 48 h. (f,g) HNE-adduct protein levels of the indicated cells treated by 1 μM DOX or VCR for 24 h. (h) The growth inhibition rates of RCC4/VHL cells treated by DOX and/or 4-HNE for 24 h. Columns, means of three independent experiments; bars, s.d. (*P<0.05,**P<0.01 for t-test).